ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.810
+0.060 (3.43%)
At close: Jul 2, 2026, 4:00 PM EDT
1.840
+0.030 (1.66%)
After-hours: Jul 2, 2026, 7:24 PM EDT
ProQR Therapeutics Employees
ProQR Therapeutics had 187 employees as of December 31, 2025. The number of employees increased by 21 or 12.34% compared to the previous year.
Employees
187
Change (1Y)
21
Growth (1Y)
12.34%
Revenue / Employee
$84,276
Profits / Employee
-$281,071
Market Cap
255.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 187 | 21 | 12.34% |
| Dec 31, 2024 | 166 | 10 | 6.07% |
| Dec 31, 2023 | 157 | 26 | 20.28% |
| Dec 31, 2022 | 130 | -51 | -28.30% |
| Dec 31, 2021 | 182 | 31 | 20.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Entrada Therapeutics | 152 |
| AC Immune | 122 |
| Invivyd | 122 |
| Niagen Bioscience | 117 |
| Orchestra BioMed Holdings | 86 |
| Fulcrum Therapeutics | 55 |
| Anavex Life Sciences | 34 |
PRQR News
- 9 days ago - ProQR Therapeutics price target lowered to $10 from $14 at Raymond James - TheFly
- 9 days ago - ProQR Therapeutics price target lowered to $10 from $11 at JonesResearch - TheFly
- 10 days ago - ProQR Therapeutics price target lowered to $3 from $4 at Chardan - TheFly
- 10 days ago - ProQR Therapeutics Slides: Conference presentation - Filings
- 10 days ago - ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering - TheFly
- 10 days ago - ProQR Therapeutics announces positive Phase 1 data for AX-0810 - TheFly
- 10 days ago - ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 10 days ago - ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform - GlobeNewsWire